International Clinics
Daily
FDA grants accelerated approval to neladalkib for ALK-positive lung cancer
On 17 November 2026 the FDA granted accelerated approval to Nelkarmi (neladalkib).
On 17 November 2026 the FDA granted accelerated approval to Nelkarmi (neladalkib).
An IAEA-coordinated research project involving 27 countries studied how biological markers can measure patients' exposure to ionising radiation.
Nothing more to show